NNVC Stock Forecast: NanoViricides, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for NanoViricides, Inc. is $6. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 52 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores NanoViricides, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (80): Reported profit is backed by cash, and the company is not expanding recklessly.
Growth (16): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
NNVC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NNVC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 July 2026 | Noble Capital Markets | Initiates | Outperform | — |
| 7 May 2024 | EF Hutton | Reiterates | Buy | — |
| 16 Feb 2024 | EF Hutton | Reiterates | Buy | — |
| 1 June 2023 | EF Hutton | Assumes | Buy | $5.25 |
| 18 Apr 2023 | EF Hutton | Reiterates | Buy | — |
| 28 Feb 2023 | EF Hutton | Maintains | Buy | $8.50 → $5.25 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NNVC.
This page is one stock. Monday covers all of them.
NNVC appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
NNVC vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, NanoViricides, Inc. returned −8.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
NNVC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 4.5×
- EV / EBITDA
- —
Cheaper than 20% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −179.2%
- Return on assets
- −85.6%
- Dividend yield
- —
Higher than 8% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
NanoViricides, Inc. has a market value of $29.1M and an enterprise value of $26.6M.
Revenue in the twelve months to 31 Mar 2026: $0.0.
Net income over the same four quarters: −$8.1M.
Free cash flow in the twelve months to 31 Mar 2026: −$7.4M, after $95K of capital spending.
NanoViricides, Inc. employs 7 people.
Data provided by Twelve Data
NNVC and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at NNVC’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own NanoViricides, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about NNVC
What is the NNVC stock price forecast for 2026-2027?
The median 12-month analyst price target for NanoViricides, Inc. is $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is NNVC stock a buy right now?
Of the 2 analysts covering NanoViricides, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NanoViricides, Inc. 52 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank NNVC?
As at 21 Nov 2026, NanoViricides, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (80 of 100).
Will NNVC stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts is $6, and Ticker Nerd's factor model ranks NanoViricides, Inc. 52 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the NNVC stock forecast for 2030?
No analyst covering NanoViricides, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NNVC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $6 over the next 12 months.
How has NNVC stock performed over the past year?
NanoViricides, Inc. returned -8.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does NanoViricides, Inc. do?
NanoViricides, Inc. is a clinical-stage biopharmaceutical company focused on developing antiviral therapies using its proprietary nanoviricide platform. The company’s current work centers on creating broad-spectrum nanomedicine drugs designed to target and neutralize virus particles before they infect healthy cells.
About NanoViricides, Inc.
NanoViricides, Inc. is a clinical-stage biopharmaceutical company focused on developing antiviral therapies using its proprietary nanoviricide platform. The company’s current work centers on creating broad-spectrum nanomedicine drugs designed to target and neutralize virus particles before they infect healthy cells. Its lead candidate, NV-387, is being developed for multiple viral infections, including respiratory viruses and other high-priority infectious diseases. NanoViricides also maintains additional antiviral programs addressing conditions such as herpes and other viral threats. The company combines drug discovery, development, and commercialization capabilities within a single business model, supporting its efforts across research, preclinical work, and clinical development. Headquartered in Shelton, Connecticut, NanoViricides occupies a niche position in the healthcare market as a developer of specialized antiviral treatments aimed at complex viral diseases.
CEO Dr. Anil R. Diwan Ph.D. · 7 employees · United States · https://www.nanoviricides.com